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The insulin-like growth factors (IGF-I and IGF-II) are small polypeptides (Mr 
-7500) that control growth of multiple cell types. Cells derived from all three 
embryonic lineages contain IGF receptors, and almost all cell types have been 
shown to respond to IGFs (79). The IGFs stimulate multiple cellular re­
sponses that are related to growth, including synthesis of DNA, RNA, and 
cellular protein (80). IGF-I and IGF-II signal cells that adequate nutrient is 
available in the microenvironment for the cell to enter the "s" phase of the cell 
cycle (7 1). Experiments conducted in Balb/c 3T3 fibroblasts have shown that 
when nutrients are deficient (usually, essential amino acids), the addition of 
IGF-I is sufficient to overcome growth arrest in the fibroblasts (41). Support 
for the concept of nutrient-dependent growth signalling derives from the 
observation that the IGFs stimulate both amino acid transport (40) and protein 
synthesis (64) in skeletal tissues and have the potential to fulfill an important 
role as mediators of tissue anabolism. 
The strongest support for the theory that the IGFs are major mediators of 
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394 CLEMMONS & UNDERWOOD 
nutrient-induced changes in anabolic responses comes from the studies that 
have analyzed IGF synthesis and secretion. The rate of IGF-I synthesis in 
tissues and its secretion into the systemic circulation is dependent not only 
upon pituitary growth hormone but also upon the availability of adequate 
nutrient intake. Administration of growth hormone to fasted rats or humans 
results in a smaller increase in plasma IGF-I concentration (60) than is 
observed when growth hormone is given to fed animals. Control of IGF 
synthesis and secretion, therefore, may provide an intermediate signalling 
mechanism that indicates to target cells that adequate nutrients have been 
ingested and are available for protein synthesis and cell division. 
Current understanding of the molecular mechanisms by which the IGFs act 
as an intermediate signal has resulted from the unraveling of a complex series 
of biochemical events that occur following nutrient intake. These studies have 
also clarified the relationship between IGF-I and insulin in nutrient-dependent 
signalling. IGF-I and insulin are structurally related: The amino acid sequence 
of proinsulin has about 50% homology with IGF-I (6 1). At one time a 
primordial precursor for insulin and IGF-I may have linked nutrient intake 
directly to stimulation of cell growth. Insulin probably evolved in order to 
provide a mechanism for sensitive control of carbohydrate balance following 
meals, whereas IGF-I has remained a more primordial stimulus that is closely 
related to total energy and protein intake. 
The conservation of the primary structures of IGF-I and insulin allows for 
some overlap in their receptor specificity (52). Thus, insulin can bind IGF 
receptors with approximately 1% the affinity of IGF-1. In several test systems, 
however, insulin is not as potent a growth stimulant as IGF-I, even at 
concentrations that appear to be sufficient to saturate IGF-I receptors. Some 
additional property, therefore, may be possessed by the IGF-I molecule that 
permits maximal stimulation of cell growth. Likewise, IGF-I and -II can 
cross-react with insulin receptors by approximately 2%, and IGF-I produces 
hypoglycemia if given in sufficient amounts (65). IGF-I, however, is not a 
potent stimulator of lipogenesis, presumably because fat cells do not contain 
IGF-I receptors (82). There is also significant conservation of structure 
between the insulin receptors and IGF receptors: 40% of the primary sequence 
of these receptors is homologous, as is their heterotetrameric structure (78). 
The insulinlIGF receptor heterotetramers are composed of two alpha subunits 
(Mr �135,000) that contain either IGF- or insulin-binding sites and two beta 
subunits (Mr �95,000) that contain a tyrosine kinase signalling domain. After 
binding of either ligand to its respective receptor, the receptor undergoes a 
confrrmational change that results in activation of tyrosine kinase activity and 
phosphorylation of specific proteins believed to be essential for IGF and 
insulin receptor signalling (38). There is also evidence of receptor cross-talk: 
activation of the IGF receptor results in activation of the insulin receptor and 
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IGFs AND NUTRITION 395 
vice versa (39). Therefore, while they have evolved specific functions con­
cerned with mediating the effects of nutrient intake on growth and metabo­
lism, the IGFs and insulin overlap binding and signal transduction properties. 
This overlap suggests that the interactions between these peptides that are 
involved in nutrient-dependent signalling mechanisms may be coordinated. 
Autocrine, Paracrine, and Endocrine Actions of IGFs 
To understand the role of IGFs in mediating the effects of nutrient intake on 
anabolic responses, it is important to realize that IGFs may function as 
autocrine/paracrine growth factors as well as classic endocrine hormones. 
Initially the IGFs were believed to be systemic growth factors, which are low 
in patients with growth hormone deficiency and high in patients with growth 
hormone excess (26). Later studies showed that many cell types in culture, 
including human fibroblasts, could secrete IGFs ( 1, 17) and that fibroblast­
related connective tissue cells in many organs contain IGF-I and IGF-II 
mRNAs (30). Since these cells are present in multiple tissues and organs, 
investigators have hypothesized that IGFs are secreted in the microenviron­
ment and stimulate cell growth locally (Figure 1). Further support for this 
hypothesis derives from the observation that addition of antibodies to IGF-I or 
to type I IGF receptors in concentrations sufficient to inhibit IGF-I binding to 
receptors will block the effects of locally secreted IGF-I on growth (10, 63). 
This hypothesis has been extended by showing that IGF-I is synthesized in 
wound injury models of cartilage, muscle, or arteries. This synthesis occurs in 
cell types that are dividing rapidly (e.g. satellite cells in muscle) and con­
tinues until the wound is healed (62). Synthesis of IGF-I, therefore, may be an 
important component of their local proliferative response to injury, and 
autocrine/paracrine secretion of IGF-I may be an essential growth regulatory 
event after injury. Nutritional intake could potentially regulate this local 
proliferative response by modulating IGF-I synthesis by cells in the regenerat­
ing tissue. This review focuses on control by nutrients of IGF secretion into 
blood. The reader, however, should keep in mind that synthesis IGF-I in 
peripheral tissues (about which little is known) may also be an important 
component of the response to changes in nutrient intake. 
The role of insulin-like growth factor II in mediating the effects of IGFs is 
incompletely understood. Possibly, IGF-II modulates nutritional effects in­
directly, since its concentrations in serum are 3---4 times greater than those of 
IGF-I, and changes in IGF-I that result in saturation of plasma-binding 
proteins might accelerate the rate of IGF-II transport out of the vascular 
compartment. Changes in extravascular IGF-I concentrations could also 
change IGF-II binding to cell surface receptors. IGF-II has 52% amino acid 
sequence identity with IGF-I and binds the type I IGF receptor with approx­
imately one third the affinity of IGF-I (56). Therefore, IGF-II has the struc-
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396 CLEMMONS & UNDERWOOD 
Figure 1 Comparison of autocrine/paracrine and endocrine control of cell growth by somatome­
dins. 
tural requirements that are necessary to stimulate growth. IGF-I1 con­
centrations in plasma are much less dependent on growth hormone than are 
IGF-I concentrations, and their role in mediating changes in the anabolic 
response to nutrient intake is unknown. To propose a direct role for IGF-II in 
mediating changes in the anabolic response to nutrient intake is difficult 
because plasma levels of IGF-II have been shown to be unchanged even by 
extreme nutrient deprivation such as 10 days of fasting (20). 
Nutritional Control of IGF-I Synthesis and Secretion 
The possible role of nutrition in the regulation of IGFs first came to light when 
Grant et al observed that serum somatomedins (IGF) bioactivity was low in 
children with protein-calorie malnutrition, despite high growth hormone (GH) 
values (29). The development of specific reagents that could reliably measure 
serum IGF-I concentrations by RIA enabled investigators to show that fasting 
of normal human subjects for 10 days resulted in a 70% fall in plasma IGF-I 
concentrations (12). The uncoupling between serum GH concentrations and 
GH action was confirmed by Merimee et al (53), who showed that after three 
days of fasting, normal subjects showed no change in serum IGF-I in response 
to GH injections. This finding suggested that the low somatomedin (IGF) 
observed in malnourished children was due to growth hormone resistance. 
Other hormones also appear to be involved in the fasting-induced decline in 
IGF-I as reflected in positive correlations between changes in serum T3 and 
insulin concentrations and changes in serum IGF-I during caloric restriction 
(9). 
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IGFs AND NUTRITION 397 
The molecular mechanisms accounting for changes in blood concentrations 
of IGF-I during nutrient deprivation have been the focus of intense analysis. 
Rat models have been used for these studies so that tissues can be sampled and 
steady-state IGF-I mRNA levels can be analyzed. Because liver is believed to 
be the primary source of IGF-I in blood, this organ has been studied most 
intensely. When rats are fasted for three days they experience marked reduc­
tions in serum IGF-I and in binding of growth hormone to its receptor (46). 
This reduction in growth hormone binding has been proposed as the primary 
mediator of growth hormone refractoriness. During refeeding, hepatic growth 
hormone binding increased at approximately the same rate as the serum IGF-I 
concentrations. The fasting-induced decline in GH binding may be an impor­
tant mechanism for the decrease in serum IGF-I concentrations. Straus & 
Takemoto (72) have recently shown that the decrease in GH receptors that 
occurs during fasting is accompanied by a parallel decrease in hepatic GH 
receptor mRNA abundance, indicating that regulation may occur at the 
transcriptional level. 
In fasted rats, steady-state hepatic IGF-I mRNA levels decrease in compari­
son with well-fed controls, thus indicating that decreased transcription of 
IGF-I mRNA may be the mechanism mediating the decrease in blood IGF-I 
concentrations (24). Indeed Straus & Takemoto (72) have shown that this 
fasting-induced reduction is accompanied by a direct reduction in the rate of 
IGF-I gene transcription. Refeeding produces a prompt increase in steady­
state mRNA levels. 
In contrast to the reduction in GH receptors that occurs during fasting, 
dietary protein restriction in rats appears to lower serum IGF-I concentrations 
by a different mechanism. Rats subjected to restriction of dietary protein (5% 
instead of 15% protein diet) show consistent reductions of serum IGF-I 
concentrations, but only modest reductions in GH binding (47). Furthermore, 
when protein-restricted rats are treated with GH they exhibit marked attenua­
tion of the serum IGF-I response (44) (Figure 2). Taken together, these 
findings suggest that protein restriction causes post-receptor resistance to the 
action of GH, and that the low IGF-I is not mediated via reduced GH binding 
(50). Protein restriction also causes reduction of hepatic IGF-I mRNA com­
mensurate with the decline in serum IGF-I (55), which suggests that the 
changes in serum IGF-I come about partly as the result of transcriptional 
events. 
Lowe et al have shown that fasting induces significant reductions in IGF-I 
mRNA abundance in nonhepatic tissues such as kidney, muscle, gut, and 
brain, indicating that these changes are not restricted to hepatic IGF-I mRNA 
(42). Furthermore, IGF-I receptor mRNA appears to be up-regulated in many 
of these organs (42). Protein deprivation in preweaning rat pups also reduces 
IGF-I mRNA abundance, thereby implicating pre-translational mechanisms 
(55). When young pups are fed a protein-restricted diet by gastrostomy their 
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Figure 2 Response of serum IGF-I to GH in protein-restricted rats. Normal rats were fed a 
normal (closed circles) or a 5% (open circles) protein diet for seven days and were given GH in 
the dosage indicated. The results show significant attenuation of the serum IGF-I response in the 
protein-restricted animals. 
weight gain and tail lengths are less than those of control animals fed a normal 
diet. Correlations can be made between liver mRNA abundance and weight 
gain (r = 0.614), increases in tail length (r = 0.579), and plasma IGF 
concentrations (r = 0.56). The effect of protein deprivation appears to be 
age-dependent, since it is less profound in older animals (25)-
The effect of energy deprivation on these molecular mechanisms has not 
been studied extensively. Several investigators have examined the effect of 
experimental diabetes as a model of energy restriction (8, 28, 45, 48, 49). 
Maes et al showed that diabetes had no effect on GH receptor number in intact 
or hypophysectomized rats; their serum IGF-I responses to GH were im­
paired, however, suggesting that diabetes had caused a post-receptor defect 
(48). Goldstein et al have shown that experimental diabetes results in a 
reduction in hepatic IGF-I mRNA abundance, and they suggest that these 
changes contribute to reduction in serum IGF-I (28). Bomfelt et al have 
confIrmed this fInding in diabetic rats and have shown the IGF-I mRNA 
abundance is also reduced in kidney, heart, and diaphragm (8). 
To determine if the reduction in the serum IGF-I response to GH is the sole 
mechanism resulting in growth retardation in protein-restricted rats, IGF-I has 
been administered to fasting mice and rats as well as to rats fed 5% protein 
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IGFs AND NUTRITION 399 
NUTRITIONAL REGULATION OF THE GH/IGF-1/IGF 
BINDING PROTEIN CASCADE 
lIGF-1 mRNA 
� 
Fasting Reduces GH Receptors 
Protein Restriction Causes 
Post-receptor Resistance to GH 
GH 
t 
\IGF-1 
1 
\IGFBP-3 
Figure 3 Sites in the GHlIGF-IJIGF binding protein cascade at which nutrient restriction 
appears to exert effects that lead to attenuation of growth. During fasting, GH receptors are 
decreased, and this may impair GH action. During protein restriction, GH binding is not 
diminished, but there is post-receptor resistance to the action of GH. Nutrient restriction also 
decreased IGF binding protein-3, the principal serum carrier of IGFs. This, in turn, reduces 
serum IGF concentrations. Finally, protein restriction causes resistance of some tissues to the 
growth-promoting effects of IGF-1. 
diets. If IGF-I is infused into starved mice (58) at a rate that maintains IGF-I 
levels similar to those in nonstarved animals, the rate of weight loss can be 
attenuated significantly for 36 hr. In contrast, GH has no effect. This finding 
suggests that the IGF-I has a direct role in mediating the fasting-induced 
changes in body mass. IGF-I infusion into rats who are fasted causes a 
reduction in protein degradation but produces no change in protein synthesis 
(37). Likewise, infusion of IGF-I into rats fed 5% protein diets does not 
restore the normal rate of increase in tail length, weight, or tibial epiphyseal 
width (76). This observation suggests that protein deficiency not only lowers 
serum IGF-I concentrations in response to GH but also produces refractori­
ness to IGF-I action. Interestingly, protein-deficient rats infused with IGF-I 
increase their serum IGF binding protein-3 (IGFBP-3) concentrations, 
suggesting that some actions of IGF-I are not impaired. Hirschberg & Kopple 
showed that renal plasma flow increases when IGF-I is infused into in fasted 
rats, which suggests that this response is also maintained in kidney (33). 
In summary, nutrient restriction appears to produce resistance to IGF-I and 
to GH action, and the mechanisms that mediate this resistance may be 
manifest at multiple points in the IGF biosynthetic pathway (Figure 3). IGF 
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400 CLEMMONS & UNDERWOOD 
synthesis is impaired in the liver during fasting because of reduction of growth 
hormone receptors. Less stringent diet manipulations such as protein restric­
tion appear to cause post-receptor defects in GH action. Basal rates of 
transcription, however, are reduced by protein restriction in rapidly growing 
rats, but basal levels of transcription are maintained in adult rats, and transla­
tion of IGF-I mRNA appears to be impaired. Finally, impairment of IGF-I 
action appears to occur at the cellular level, and delivery of IGFs out of the 
vascular compartment to tissues may be impaired in animals fed 5% protein 
diets. 
Nutritional Control of Plasma Concentrations of IGF-I in 
Humans 
Reports of the changes in serum concentrations of IGF-I in response to dietary 
restriction in normal human subjects have revealed striking decreases in 
serum IGF-1. To define the macronutrient requirements necessary to maintain 
a normal serum IGF-I concentration, Isley et al fasted normal subjects for five 
days and then refed them three separate test diets containing different amounts 
of protein and energy. Fasting caused a 67% fall in IGF-I (35). Refeeding a 
control diet containing 35 kcal and 1 g protein per kilogram ideal body weight 
(IBW) increased the IGF-I values to more than 70% of control values in 5 
days (approximately 8 days are required to return to 100% of the control 
level). In contrast, if the subjects were refed a protein-deficient, energy­
sufficient diet (40% of the recommended daily protein intake), the IGF-I 
increased to 55% of control values in 5 days, significantly less than the 
increase with the control diet (35) (Figure 4). If the subjects received a diet in 
which energy and protein were restricted, the values continued to decline over 
the next 5 days. The change in IGF-I during each fast-refeed cycle correlated 
with the mean daily nitrogen balance (r = 0.90). This correlation, however, 
did not appear to hold for changes in absolute protein balance. Rather, it 
reflects the acute directional changes in nitrogen balance that occur during 
fasting and refeeding. This finding suggested that measurement of IGF-I 
concentrations might predict whether a diet was adequate to significantly 
improve protein balance. 
To further define the amounts of food needed to effect these changes, 
normal volunteers were fasted for 5 days and then refed test diets during 
sequential 9-day periods. One set of these diets contained adequate energy but 
incremental amounts of protein, while the other set contained adequate pro­
tein, with incremental amounts of energy. Fasting for 5 days caused a 
70-75% decline in IGF-I (36). During the 9-day refeeding periods, diets of 
the lowest energy and protein content resulted in minimal changes in IGF-1. If 
0.2/kg IBW protein was refed (adequate energy), a statistically significant 
28% rise in IGF-I occurred; but if 11 kcal/kg was fed (adequate protein), there 
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NORMAL DIET 
I LOW PROTEIN /1" ""1 NORMAL ENERGY 
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Figure 4 Change in somatomedin-C in response to fasting and refeeding. Five normal weight 
volunteers were fasted for 3 separate 5-day intervals and then were refed diets consisting of 1.0 g 
protein and 35 kcal/kg (normal diet), 0.4 g protein and 35 kcallkg (low protein), or 0.4 g protein 
and 11 kcal/kg (low protein, low energy). The results show that combined energy and protein 
restriction prevents any increase in somatomedin-C in response to refeeding, whereas protein 
restriction attenuates the somatomedin-C response. 
was no significant change in IGF·I. These findings suggest that the minimal 
requirement for calories is absolute and that a threshold quantity of energy 
must be provided for normal volunteers to increase their plasma con­
centrations of IGF-I. In contrast, at each level of protein intake (adequate 
energy) an incremental increase in serum IGF-I occurred. Specifically, the 
IGF·I values achieved at 0.4 g/kg IBW were significantly greater than those 
achieved at 0.2 g/kg. IGF-I was normalized when 1 g protein per kilogram 
IBW was ingested. In terms of energy, the subjects had to be refed 18 kcal/kg 
IBW to obtain a significant increase in serum IGF-I, and maximal con­
centrations were achieved at 25 kcal/kg IBW. In this study also, an excellent 
correlation was found between changes in IGF·I induced with each diet and 
the acute directional change in nitrogen balance. 
Although we assumed that the nutritionally dependent changes in plasma 
IGF-I were due to refractoriness to GH, the precise degree of dietary restric­
tion needed to produce GH refractoriness was not defined. Therefore, we 
have carried out studies to test the effect of caloric restriction on the IGF·I 
response to growth hormone. If obese subjects are fed a diet containing 24 
kcallkg IBW, no change in basal serum IGF-I levels is observed over a period 
of 3 weeks (14). If exogenous growth hormone is administered, a 2.8-fold 
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U 
I 
.� 
.., 
<II 
E 
o 
c 
E o 
(/) 
.. u c c 
c 
al -
c .. 
'" 
e 
z 
.-. Cl Growth Hormone 
Study Day 
Figure 5 Changes in nitrogen balance and somatomedin-C (IGF-I) responses to growth hor­
mone. GH was administered (0.1 mg/kg ideal body weight q.o.d.) to obese subjects who were fed 
a calorically restricted diet (24 kcal/kg per day). The results show that GH was capable of 
inducing an anabolic response under these conditions. 
increase in serum IGF-I concentrations is observed indicating minimal or no 
attenuation in plasma IGF-I responsiveness to GH (Figure 5). All subjects 
entered positive nitrogen balance while receiving GH, which indicates that 
this 24 kcallkg diet had exerted little or no effect on their responsiveness. 
When more severe caloric restriction is imposed, however, effects are 
observed. In obese subjects fed 18 kcallkg IBW for a period of 1 1  weeks and 
given GH every other day at a dose of 0.1 mg/kg IBW, IGF-I responses were 
normal at the beginning of GH therapy (approximately 3.I-fold increase) 
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IGFs AND NUTRITION 403 
(69). Likewise, these subjects achieved positive nitrogen balance, but this 
response was attenuated over time, and after 5 weeks no difference in nitrogen 
balance between GH treated and control diet-restricted subjects was observed. 
Since IGF-I responsiveness remained for the entire 11 weeks, we concluded 
that the subjects had become refractory to IGF-I after 5 weeks. This observa­
tion in humans may be comparable to that seen in rats fed 5% protein diets, 
who did not grow when infused with IGF-I, and suggests that an early effect 
of caloric restriction is attenuation of IGF-I responsiveness. Manson & Wil­
more also noted that normal-weight subjects fed a similar level of energy 
could respond to GR with a 2. I-fold increase in IGF-I (51). 
To determine the degree of caloric restriction required to attenuate the 
IGF-I response to GR, we fed obese subjects a diet containing 12 kcallkg 
IBW and administered growth hormone. These subjects had a prompt IGF-I 
response to GR, although it was significantly attenuated compared to the 
response of subjects that were fed 18 kcal/kg IBW, (i.e. a 1.8-fold compared 
to a 3. I-fold increase) (70). Unlike the response of subjects fed 18 kcal/kg, 
the IGF-I response of subjects fed 12 kcal/kg began to attenuate quickly. After 
three weeks no significant differences were found between plasma IGF-I 
concentrations in the growth hormone-treated versus nongrowth hormone­
treated subjects (70). Attenuation of nitrogen retention was significant, so that 
by the third week no differences in urinary nitrogen excretion were found 
between control and growth hormone-treated subjects. These findings suggest 
that more severe caloric restriction results not only in refractoriness of the 
IGF-I synthetic mechanism but also in refractoriness to IGF-I at the tissue 
level. Whether or not this refractoriness is mediated at the translational level 
or transcriptional level is unknown. 
We have observed that the attenuation of the IGF-I response can be 
partially overcome by increasing the dose of growth hormone (67). When we 
gave twice as much growth hormone as in our previous studies, IGF-I 
responsiveness was sustained, but by the third week the nitrogen balance 
response began to attenuate, suggesting that the subjects had become refrac­
tory to IGF-I during the last two weeks of GR administration (67). 
To further elucidate the role of nutrients in the development of sensitivity to 
growth hormone, we have studied the effect of refeeding of essential amino 
acids in increasing IGF-I secretion after fasting (13). Normal subjects were 
fasted for five days, then refed test diets containing approximately one half of 
a normal nitrogen intake. In one diet, 80% of the nitrogen was supplied as 
essential amino acids while in the other 80% was supplied as nonessential 
amino acids (13). After five days of refeeding, serum IGF-I was significantly 
greater in the subjects fed essential amino acids than in those fed nonessential 
amino acids. The final concentration of IGF-I was approximately 22% higher 
with the essential amino acid diet, indicating that ingestion of essential amino 
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404 CLEMMONS & UNDERWOOD 
acids is required to attain an optimal IGF-I response to refeeding. As in other 
studies, an excellent correlation was found between changes in nitrogen 
balance that were induced by protein restriction and changes in blood IGF-I 
concentrations. 
To determine if measurements of serum IGF-I have utility in predicting the 
responses of catabolic patients to refeeding, seven chronically undernourished 
subjects, most of whom had decreased nutrient absorptive capacity, were 
given hyperalimentation therapy ( 16). These subjects had lost between 3 and 
21 kg in the year prior to study. All subjects were more than 10% below IBW 
at entry into the study. The nutrient repletion was accomplished by enteral or 
parenteral feedings, or both. The caloric intake ranged between 32.7 and 42.6 
nonprotein kcallkg and the nitrogen intake was between 0.22 and 0.34 g/kg. 
The subjects' mean serum IGF-I concentration was approximately 0.67 ± 
0.1 5  D/ml and rose 3-fold to 1 .8 ± 0.44 D/ml after 10 days of hyperalimenta­
tion therapy. The increase in serum IGF-I correlated with the change in 
cumulative nitrogen balance (r =:: 0.88). In contrast to the IGF-I results, no 
change in transferrin, retinol-binding protein, or prealbumin was noted during 
therapy. Following their peak IGF-I response after 10 days of nutrient reple­
tion, the subjects had a decline in IGF-I despite continued hyperalimentation 
therapy. An overshoot phenomenon such as we observed has been described 
for protein turnover by Golden et al while refeeding children with proteinl 
calorie malnutrition (27). Our findings suggest that, as in normal individuals, 
changes in protein balance may correlate with changes in IGF-I con­
centrations during therapy of malnourished patients. These findings were 
confirmed by Donahue & Phillips (22), who showed that nutritional support 
therapy of 15 hospitalized malnourished patients caused a 264% increase in 
serum IGF-I concentrations, but produced no significant change in albumin or 
transferrin. Changes in IGF-I correlated with changes in nitrogen balance in 
that study (22). These findings are supported by recent studies showing that 
IGF-I levels correlate with improvement in nitrogen balance in critically ill 
patients (32) and with body size in low birth weight infants (54). 
To determine the role of excessive energy expenditure on nitrogen balance 
and serum IGF-I, normal subjects were exercised intensely for a period of one 
week but were maintained on a diet containing normal amounts of energy (35 
kcallkg) (66). The intensive exercise was sufficient to account for the ex­
penditure of 1 3  kcallkg of energy. This energy deficit resulted in a decrease in 
serum IGF-I concentrations of approximately 40% despite the fact that these 
exercising subjects should have had increased growth hormone secretion. 
Likewise, if these same subjects remained sedentary and were fed a diet with 
an equivalent degree of energy restriction (e.g. 22 kcallkg), they experienced 
approximately the same reduction in serum IGF-I concentrations. This finding 
indicates that loss of calories through utilization during exercise results in the 
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IGFs AND NUTRITION 405 
same decrement in IGF-I concentration as does dietary-induced caloric 
restriction. This study also showed that protein was conserved in the exercis­
ing subjects. Specifically, during the last 3 days of diet restriction, daily 
nitrogen balance was -3.50 ± 1.73 g per day, whereas it was -1.60 ± 1.07 
g per day during exercise (p < 0.05). 
Studies on the effects of GH on IGF-I secretion and the effects of IGF-I on 
protein balance are limited in patients who are catabolic because of severe 
medical and surgical illnesses. Ward et al (81) showed that postoperative 
patients whose energy intake was restricted severely (e.g. 400 kcal per day) 
responded to GH with a significant increase in protein synthesis. Although the 
rate of protein breakdown also increased, the increase in protein synthesis 
exceeded the protein breakdown, and the subjects entered positive protein 
balance. Zeigler et al showed that GH improved nitrogen balance by 3.4 gm 
per day in postoperative patients who were receiving 1100 kcal per day (83). 
We studied 7 malnourished patients with undernutrition associated with 
chronic obstructive pulmonary disease (COPD) who were between 78 and 
89% of ideal body weight. All subjects had significant weight gain and 
improvement in nitrogen balance on GH (59). Nitrogen balance increased 
from 1.6 to 3.3 g per day, and, most importantly, muscle strength as assessed 
by measurement of inspiratory force showed a significant increase. These 
studies indicate that patients who are catabolic may benefit not only from 
nutritional supplementation but also from pharmacologic agents that increase 
IGF-I above the levels that can be achieved by supplementation of nutrients 
alone. 
Insulin-like Growth Factor Binding Proteins and Nutrition 
The insulin-like growth factor binding proteins (lGFBPs) are high affinity, 
soluble carrier proteins that circulate in blood and extracellular fluids and 
appear to control IGF transport, efflux from the vascular compartment, and 
association of IGF with cell surface receptors. Understanding their role in 
determining how nutrient intake may influence IGF-I and -II actions is 
critical, since they control availability of IGFs to tissues, and their secretion is 
also controlled by nutrient intake (5). IGFBP-l is a 2S-kDa protein whose 
plasma concentrations fluctuate widely over a 24 h period (4). IGFBP-2 is a 
31-kDa protein whose plasma concentrations are somewhat more stable than 
those of IGFBP-l and are significantly higher in fetal than in postnatal life. 
IGFBP-l binds IGF-I and -II with approximately equal affinity, whereas 
IGFBP-2 has an approximately threefold greater affinity for IGF-II. IGFBP-3 
is a 53-kDa glycoprotein that associates with an acid labile, nonbinding 
subunit in serum and with IGF to form a lSO-kDa complex (6). This complex 
apparently prevents rapid vascular efflux of IGF-I and -II from the vascular 
compartment and stabilizes the concentrations of IGFs in blood. The primary 
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406 CLEMMONS & UNDERWOOD 
function of IGFBP-3 may be to act as a carrier of IGFs in the circulation, 
whereas the primary functions of IGFBP-l and -2 may be to transport IGF 
across the endothelial surface to specific cell types (3). If these proteins serve 
different functions, it is reasonable to assume that regulation of their secretion 
may be different. For example, growth hormone and IGF-I both induce the 
synthesis and secretion of IGFBP-3, and increase its concentrations in plasma 
(15). In contrast, IGFBP-I and -2 are both suppressed by growth hormone 
(31), and IGF-I directly stimulates the secretion of IGFBP-2, whereas it often 
inhibits IGFBP-I (77). 
Nutrient intake is a major regulator of the plasma concentrations of these 
proteins. Prolonged fasting and/or protein deficiency results in significant 
reduction in serum IGFBP-3 concentrations (15). Likewise, refeeding either 
normal energy or normal protein intake will increase the concentrations of this 
peptide. IGFBP-3, however, is not affected by acute changes in nutrient 
intake, and its plasma concentrations remain stable throughout the day (5). 
The fact that IGFBP-3 is the major carrier of IGF-I probably accounts for the 
stability of IGF-I in blood. Protein restriction has also been shown to increase 
hepatic IGFBP-2 mRNA abundance, although its effects on the serum con­
centrations of IGFBP-2 are unknown (73). Other nutritional factors affecting 
IGFBP-2 are not well delineated, although states of extreme insulin de­
ficiency, e.g. starvation, for nine days or uncontrolled diabetes have been 
shown to increase plasma concentrations. In contrast, acute alterations in 
caloric intake have minimal effects on plasma IGFBP-2 concentrations. 
Unlike IGFBP-2 and -3, IGFBP-I is markedly suppressed by ingestion of 
food. This change is believed to be due to insulin secretion, since infusion of 
insulin into normal subjects suppresses IGFBP-l (75), and the degree of 
suppression correlates in clamp studies with the degree of insulin-stimulated 
glucose transport (74). In type I diabetics the magnitude of the nocturnal 
increase in plasma IGFBP-l is greater in under-insulinized and less in over­
insulinized patients (34). In normal subjects infused with glucose the suppres­
sion of IGFBP-l correlates with stimulation of c-peptide (r = 0.74) (68). 
However, glucose itself appears to have some direct suppressive effect be­
cause infusion of isocaloric amounts of fructose (which does not stimulate 
c-peptide secretion) causes suppression of IGFBP-l that is about one half that 
caused by glucose infusion. This result suggests that both insulin-dependent 
and insulin-independent factors control IGFBP-l secretion (68). Changes in 
plasma IGFBP-l  are accompanied by changes in hepatic IGFBP-l mRNA. 
Fasting and/or insulin deficiency result in increasing amounts of IGFBP-l 
mRNA in rat liver, and this mRNA is reduced by manipulations that raise 
insulin secretion (57). 
The rapidity of the insulin-induced fall of IGFBP-l concentrations has led 
several investigators to suggest that this decline may be secondary to accelera-
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IGFs AND NUTRITION 407 
tion of IGFBP transport. Bar et al showed that perfusion of the isolated rat 
heart system with insulin plus IGFBP-l caused accelerated IGFBP-l transport 
across the extravascular space, whereas IGFBP-2 transport was unaffected 
(2). Thus, insulin may selectively stimulate the translocation of IGFBP-l 
under the influence of caloric intake. 
Changes in the plasma concentrations of binding proteins could lead to 
changes in tissue distribution of IGF-I and IGF-II. Davenport et al have 
shown that reduction of IGFBP-3 in pregnant rat plasma leads to a marked 
alteration in the rate of tissue clearance and metabolism of radiolabeled IGF-I 
(19). Changes in nutrient intake, therefore, may not only alter IGF-I synthesis 
but also may change its rate of transport and its clearance in tissues. All of 
these changes may have important effects on IGF action. 
Control of IGF Action by Binding Proteins 
The molecular mechanisms by which the IGFs improve protein balance and 
growth are not completely understood. Following their secretion, the IGFs are 
bound to the high affinity IGF carrier proteins. Both IGFBP-3 and IGFBP-I 
are present in extracellular fluids and modulate IGF action at the surface of 
target cells (21, 28). IGF-binding proteins were originally thought to simply 
act as a reservoir, preventing saturation of receptors and maintaining a 
constant egress of IGF off the binding protein-IGF complex and onto cell 
surface IGF receptors. Experiments in cell culture, however, suggest that a 
more complex phenomenon exists. In human fibroblasts, for example, 
IGFBP-3 is synthesized but then resides on the cell surface for a period of 
time prior to its secretion into medium (43). IGFBP-3 has such high affinity 
for IGF-I, however, that it preferentially binds the IGF-I that is present in the 
medium, and possibly these two proteins are co-secreted by the fibroblast. 
Addition of exogenous IGF-I results in displacement of IGF-I from soluble 
IGFBP-3 and makes it available to bind to cell surface-associated type I IGF 
receptors and IGFBP-3 (43). Because IGFBP-3 in culture medium has a 
higher affinity for IGF-I than either cell-associated binding proteins or recep­
tors, it directs the amount of growth factor that binds to either moiety. 
Likewise, if sufficient amounts of IGFBP-l and IGFBP-2 become cell surface 
associated, they exhibit the same kinetic phenomenon. 
The metabolic consequences of this alteration in binding are not understood 
completely; however, it is clear that IGFBP-3 can potentiate the response to 
IGF·1. When added exogenously to MDBK cells or cultured human fibro· 
blasts, coequal amounts of IGFBP·3 and IGF·I result in approximately 40% 
potentiation of the effect of IGF·I alone on the rate of cell growth (18). This 
response also occurs in BHK cells (7). If excessive amounts of IGFBP-3 are 
added, however, inhibition of cell growth takes place, which suggests that 
some optimal rate of transfer of IGF-I from IGFBp·3 onto the receptor is 
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408 CLEMMONS & UNDERWOOD 
necessary for maximal target cell responsiveness. These studies raise the 
possibility that nutritional control of IGFBP-3 secretion at the cellular level 
may be an important modulator of target tissue cell responsiveness and could 
be an important mediator of tissue refractoriness to IGF-1. 
Like IGFBP-3, IGFBP-l is also a potent bimodulator of growth responsive­
ness to IGF-I. When quiescent smooth muscle cells are exposed to IGFBP-l 
plus IGF-l ,  a 5.6-fold potentiation in the rate of DNA synthesis is observed 
(23). This potentiation requires an unknown factor that is present in platelet­
poor plasma and human spinal fluid (11). IGFBP-I also competes with IGF-I 
for binding to cell surface receptors and can act as a growth inhibitor if added 
to serum-free medium at high concentrations. Because IOFBP-l con­
centrations are inversely related to serum insulin concentrations and IGFBP-l 
transport is facilitated by insulin, the immediate availability of this binding 
protein in the microenvironment as a carrier of IGF-I could provide a signifi­
cant source of IGF-I for rapid potentiation of cell growth. 
Summary 
The secretion of both IGF-I and IGF-II, peptides that are structurally related 
to insulin, is linked to nutrient intake. These growth factors and their binding 
proteins appear to be major links between nutrient intake and cellular anabolic 
responses. Understanding the mechanisms by which nutrients control IGF 
synthesis and regulate transport to target tissues should permit the formulation 
of strategies for treatment of catabolic disorders. Understanding the altera­
tions of such processes in catabolic states should enable development of better 
methods for nutritional repletion and wiser uses of anabolic agents in the 
treatment of these conditions. 
ACKNOWLEDGMENTS 
The authors gratefully acknowledge Jennifer O'Lear, who prepared the manu­
script. This work was supported by grants HL36313, A002331, HD08299, 
and HD26871 from the National Institutes of Health. 
Literature Cited 
1. Atkison, P. R.,  Weidman, E. R., 
Bhaumick, K. B.,  Bala, R.  M. 1980. 
Release of somatomedin-like activity by 
cultured WI-38 human fibroblasts. 
Endocrinology 106:2006-12 
2 .  Bar, R. S . ,  Boes, M., Clemmons, D.  
R . ,  Busby, W .  H., Sandra, A., et  al. 
1990. Insulin differentially alters trans­
capillary movement of intravascular 
IGFBP- l ,  IGFBP-2 and endothelial cell 
lGF-binding proteins in rat heart. 
Endocrinology 127:497-99 
3. Bar, R. S.,  Clemmons, D. R.,  Boes, 
M., Busby, W. H., Booth, B. A., et al. 
1990. Transcapillary permeability and 
subendothelial distribution of endothe­
lial and amniotic fluid IGF-binding pro­
teins in rat heart. Endocrinology 127: 
1078-86 
4. Baxter, R. C . ,  Cowell, C. T. 1987. Di­
urnal rhythm of growth hormone­
independent binding protein for insulin­
like growth factors in human plasma. J. 
Clin. Endocrinol. Metab. 65:432-40 
A
nn
u.
 R
ev
. N
ut
r. 
19
91
.1
1:
39
3-
41
2.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
5. Baxter, R. c., Martin, J. L. 1989. Bind­
ing proteins for insulin-like growth fac­
tors: structure, regulation and function. 
Prog. Growth Factor Res. 1:49-68 
6. Baxter, R. C., Martin, J. L., Beniac, V. 
A. 1989. High molecular weight insulin­
like growth factor binding protein com­
plex: purification and properties of the 
acid-labile subunit from human serum. 
J. Bioi. Chem. 264:11843-48 
7. Blum, W. F., Jenne, E. W., Reppin, F., 
Kietzmann, K., Ranke, M. B., Bierich, 
1. R. 1989. Insulin-like growth factor I 
(IGF-I) binding protein complex is a bet­
ter mitogen than free IGF-1. Endocrinol­
ogy 125:766--72 
8. Bomfelt, K. E., Amqvist, H. J., En­
berg, B., Mathews, L. S., Norstedt, O. 
1989. Regulation of insulin-like growth 
factor-I and growth hormone receptor 
gene expression by diabetes and nutri­
tional state in rat tissues. J. Endocrinol. 
122:651-56 
9. Caufriez, A., Golstein, J., Lebrun, P., 
Herchuelz, A., Furlanetto, R., Copins­
chi, G. 1984. Relations between im­
munoreactive somatomedin-C, insulin 
and T3 patterns during fasting in obese 
subjects. Clin. Endocrinol. 20:65-70 
10. Clemmons, D. R., Elgin, R. G., Han, 
V. K. M., Casella, S. J., D'Ercole, A. 
J., Van Wyk, J. J. 1986. Cultured fibro­
blast monolayers secrete a protein that 
alters the cellular binding of somatome­
din-C/insulin-like growth factor I. J. 
Clin. Invest. 77:1548-56 
II. Clemmons, D. R., Gardner, L. I. 1990. 
A factor contained in plasma is required 
for IGF-binding protein-I to potentiate 
the effect of IGF-I on smooth muscle 
cell DNA synthesis. 1. Cell. Physiol. 
145:129-35 
12. Clemmons, D. R., Klibanski, A., Un­
derwood,L. E., McArthur, 1. W., Ridg­
way, E. C., Van Wyk, J. J. 1981. 
Reduction of plasma immunoreactive 
somatomedin-C during fasting in hu­
mans. 1. CUn. Endocrinol. Metab. 53: 
1247-50 
13. Clemmons, D. R., Seek, M. M., Un­
derwood, L. E. 1985. Supplemental es­
sential amino acids augment the somato­
medin-C/insulin-Jike growth factor-I re­
sponse to refeeding after fasting. 
Metabolism 34:391-95 
14. Clemmons, D. R., Snyder, D. K., Wil­
liams, R., Underwood, L. E. 1987. 
Treatment with growth hormone con­
serves lean body mass during dietary 
restriction in obese subjects. J. Clin. En­
docrinol. Metab. 64:878-83 
15. Clemmons, D. R., Thissen, J. P., Maes, 
M., Ketelslegers, J. M., Underwood, 1. 
IGFs AND NUTRITION 409 
E. 1989. Insulin-like growth factor-I 
(lGF-I) infusion into hypophysecto­
mized or protein-deprived rats induces 
specific IGF binding proteins in serum. 
Endocrinology 125:2967-72 
16. Clemmons, D. R., Underwood, L. E., 
Dickerson, R. N., Brown, R. 0., Hak, 
L. J., et al. 1985. Use of somatomedin­
Clinsulin-like growth factor I measure­
ments to monitor the response to nutri­
tional repletion in malnourished pa­
tients. Am. J. CUn. Nutr. 41:191-98 
17. Clemmons, D. R., Underwood, L. E., 
Van Wyk, J. J. 1981. Hormonal control 
of immunoreactive somatomedin pro­
duction by cultured human fibroblasts. 
J. CUn. Invest. 67:10-19 
18. Cohick, W. S., McCusker, R. H., 
Clemmons, D. R. 1990. Insulin-like 
growth factor binding proteins (lGFBPs) 
modulate IGF-I binding and cell growth 
responses of MDBK cells. Presented to 
the Endocrine Soc., June 21, Atlanta, 
Georgia, Abstr. 284 
19. Davenport, M. 1., Clemmons, D. R., 
Miles, M. W., Camacho-Hubner, C., 
D'Ercole. A. J., Underwood. L. E. 
1990. Regulation of serum insulin-like 
growth factor I (IGF-I) and IGF binding 
proteins during rat pregnancy. 
Endocrinology 127: 1278-86 
20. Davenport, M. L., Svoboda, M. E., 
Koerber, K. 1., Van Wyk, J. J., Clem­
mons, D. R .. Underwood, 1. E. 1988. 
Plasma concentrations of insulin-like 
growth factor II OGF-II) are not changed 
by short-term fasting and refeeding. J. 
Clin. Endocrinol. Metab. 67:1231-36 
21. De Mellow, J. S. M., Baxter, R. C. 
1988. Growth hormone dependent in­
sulin-like growth factor binding protein 
both inhibits and potentiates IGF-I 
stimulated DNA synthesis in skin fibro­
blasts. Biochem. Biophys. Res. Com­
mun. 156:199-204 
22. Donahue, S. P., Phillips, L. S. 1989. 
Response of IGF-I to nutritional support 
in malnourished hospital patients: a 
possible indicator of short-term changes 
in nutritional status. Am. J. CUn. Nutr. 
50:962-69 
23. Elgin, R. G., Busby, W. H., Clem­
mons, D. R. 1987. An insulin-like 
growth factor binding protein enhances 
the biological response to IGF-1. Proc. 
Natl. Acad. Sci. USA 84:3254-58 
24. Emler, C. A., Schalch, D. S. 1987. Nu­
tritionally-induced changes in hepatic in­
sulin-like growth factor I (IGF-I) gene 
expression in rats. Endocrinology 
120:832-34 
25. Fliesen. T .. Maiter. D .. Gerard. G .. Un­
derwood, 1. E., Maes, M., Kete1sleg-
A
nn
u.
 R
ev
. N
ut
r. 
19
91
.1
1:
39
3-
41
2.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
410 CLEMMONS & UNDERWOOD 
ers, J. M. 1989. Reduction in insulin­
like growth factor I by dietary protein 
restriction is age dependent. P ediatr. 
Res. 26:415- 1 9  
26. Furlanetto, R.  W . ,  Underwood, L .  E., 
Van Wyk, J .  J . ,  D'Ercole, A. J. 1977. 
Estimation of somatomedin-C levels in 
normals and patients with pituitary dis­
ease by radioimmunoassay. J. Clin. In­
vest. 60:648-57 
27. Golden, M., Waterlow, J. R., Picou, D. 
1977. The relationship between dietary 
intake, weight gain, nitrogen balance 
and protein turnover in man. Am. J. 
Clin. Nutr. 30: 1 345-48 
28. Goldstein, S . ,  Sertich, G. J . ,  Levan, K .  
R . ,  Phillips, L .  S .  1988. Nutrition and 
somatomedin. 1 9 .  Molecular regulation 
of insulin-like growth factor I in 
streptozotocin-diabetic rats . Mol. En­
docrinol. 2 : 1 093-1 100. 
29. Grant, D. B . ,  Hambley, J., Becker, D . ,  
Pimstone, B .  L .  1973 . Reduced sulpha­
tion factor in undernourished children. 
Arch. Dis. Child. 48:596-600 
30. Han, V. K. M . ,  D'Ercole, A. J . ,  Lund, 
P. K. 1 987. Cellular location of somato­
medin (insulin-like growth factor) 
messenger RNA in the human fetus. Sci­
ence 236 : 193-97 
31. Hardouin, S . ,  Gourmelen, M . ,  Noguiez, 
P., Seurin, D., Roghani, M . ,  et al. 
1989. Molecular forms of serum insulin­
like growth factor (IGF)-binding pro­
teins in man: relationship with growth 
hormone and IGFs and physiological 
significance. J. Clin. Endocrinol. 
Metab. 69: 1 291-1301. 
32. Hawker, F. H., Stewart, P. M., Baxter, 
R. c . ,  Borkmann, M . ,  Tan, K . ,  et al. 
1 987. Relationship between somatome­
din-C/insulin-like growth factor I levels 
to conventional nutritional indices in cri­
tically ill patients. Crit. Care Med. 
1 5 :732-36 
33. Hirschberg, R . ,  Kopple, J. D. 1989. 
Evidence that insulin-like growth factor 
I increases renal plasma flow and glom­
erular filtration rate in fasted rats. J. 
Clin. Invest. 83:326-30 
34. Holly, J .  M. P . ,  Smith, C. P . ,  Dunger, 
D. B . ,  Howell ,  R. J. S . ,  Chard, T., et 
al. 1989. Relationship between the 
pubertal fall in sex hormone binding 
globulin and insulin-like growth factor 
binding protein-I. A synchronized ap­
proach to pubertal development? Clin. 
Endocrinol. 3 1 :277-84 
35. Isley, W. L . ,  Underwood, L. E . ,  Clem­
mons, D. R. 1983. Dietary components 
that regulate serum somatomedin-C in 
humans. J. Clin. Invest. 7 1 : 1 75-82 
36. Isley, W. L . ,  Underwood, L. E., Clem-
mons, D. R. 1984. Changes in plasma 
somatomedin-C in response to ingestion 
of diets with variable protein and energy 
content. J. Parenter. Enter. Nutr. 8: 
407-11 
37.  Jacob, R., Barrett, E., Plewe, G. ,  
Fagin, K. D. ,  Sherwin, R. S.  1989. 
Acute effects of insulin-like growth fac­
tor I on glucose and amino acid metabo­
lism in the awake fasted rat. J. Clin. 
Invest. 83:1717-23 
38. Kadowaki, T., Koyasu, S . ,  Nishida, E . ,  
Tobe, K., Izumi, T . ,  et al. 1987. Tyro­
sine phosphorylation of common and 
specific sets of cellular proteins rapidly 
induced by insulin, insulin-like growth 
factor I and epidermal growth factor in 
an intact cell. J. Bioi. Chern. 262:7342-
50 
39. Kahn, C. R . ,  White, M. F. 1988. The 
insulin receptor and molecular mech­
anisms of insulin action. J. Clin. Invest. 
82: 1 1 5 1-56 
40. Kaplowitz, P. B . ,  D'Ercole, A. J., Un­
derwood, L. E . ,  Van Wyk, J. J. 1984. 
Stimulation by somatomedin-C of 
aminoisobutyric acid uptake in human 
fibroblasts: A possible test for cellular 
responsiveness to somatomedin.  J. Clin. 
Endocrinol. Metab. 58:176-81 
4 1 .  Leof, E. B . ,  Wharton, W . ,  Van Wyk, J .  
J . ,  Pledger, W. J .  1982 . Epidermal 
growth factor and somatomedin-C regu­
late G, progression in competent BALBI 
c 3T3 cell. Exp. Cell Res. 141:107-15 
42.  Lowe, W .  J. ,  Adamo, M . ,  Werner, H . ,  
Roberts , C.  T. , LeRoith, D .  1989. 
Regulation by fasting of insulin-like fac­
tor I and its receptor: Effects on gene 
expression and binding. J. Clin. Invest. 
84:61 9-26 
43. McCusker, R. H . ,  Camacho-Hubner, 
C . ,  Bayne, M. L. ,  Cascieri, M. A . ,  
Clemmons, D. R. 1990. Insulin-like 
growth factor (IGF) binding to human 
fibroblast and globlastoma cells: The 
modulating effect of cell released IGF 
binding proteins (lGFBPs). J. Cell. 
Physiol. 144:244--53 
44. Maes, M . ,  Amand, Y. , Underwood, L. 
E . ,  Maiter, D., Ketelslegers, J. M. 
1988. Decreased serum insulin-like 
growth factor I response to GH in 
hypophysectomized rats fed a low pro­
tein diet: Evidence for a post receptor 
defect. Acta Endocrinol. 1 1 7:320-26 
45. Maes, M . ,  Ketelslegers, J. M . ,  Un­
derwood, L. E. 1983. Low plasma 
somatomedin-C in streptozotocin-in­
duced diabetes mellitus: Correlation 
with changes in somatogenic and lacto­
genic sites. Diabetes 32:1060-69 
46. Maes, M . ,  Underwood, L. E . ,  Ke-
A
nn
u.
 R
ev
. N
ut
r. 
19
91
.1
1:
39
3-
41
2.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
telslegers, I. M .  1983. Plasma somato­
medin-C in fasted and refed rats: Close 
relationship with changes in liver 
somatogenic (GH) but not lactogenic 
(PRL) binding sites. J. Endocrinol. 
97:243-52 
47. Maes, M . ,  Underwood, L. E . ,  Ketel­
slegers, J. M. 1 984. Low somatome­
din-C in protein deficiency: Relationship 
with changes in liver somatogenic and 
lactogenic binding sites. Mol. Cell. En­
docrinol. 37:301-9 
48. Maes, M . ,  Underwood, L.  E . ,  Ketel­
slegers, J. M .  1986. Low serum soma­
tomedin-C in insulin-dependent di­
abetes: Evidence for a post receptor 
mechanism. Endocrinology 1 18 :377-82 
49. Maiter, D . ,  Fiiesen, T., Underwood, L. 
E. ,  Maes, M.,  Gerard, G. , et al . 1989. 
Dietary protein restriction decreases in­
sulin-like growth factor-I (lGF-I) in­
dependent of insulin and liver growth 
hormone binding. Endocrinology 124 : 
2604-1 1 
50. Maiter, D. M . ,  Maes, M . ,  Underwood, 
L. E. , Fliesen, T . ,  Gerard, G . ,  Ketel­
slegers, J. M. 1988. Early changes in  
serum concentrations of somatomedin-C 
induced by dietary protein deprivation: 
Contributions of growth hormone recep­
tor and post-receptor defects. J. Endoc­
rinol. 1 18:1 1 3-20 
5 1 .  Manson, 1. M . ,  Wilmore, D. W. 1 986. 
Positive nitrogen balance with growth 
hormone and hypocaloric intravenous 
feeding. Surgery 100: 1 88-97 
52. Marshall, R. N . ,  Underwood, L. E., 
Voina, S .  I . ,  Foushee , D. B . ,  Van Wyk, 
J. J .  1 974. Characterization of insulin 
and somatomedin receptors in human 
placental membranes. J. Clin . Endocri­
nolo Metab. 39:283-92 
53.  Merimee, T. J . ,  Zapf, J . ,  Froesch, E. R .  
1 982. Insulin-like growth factors in fed 
and fasted states. J.  Clin. Endocrinol. 
Metab. 55:999-1002 
54. Mitchell, M. L., Hermos, R. J., Fein­
gold, M.,  Moses, A. C. 1989. The 
relationship of insulin-like growth fac­
tor-I to total thyroxine in normal and low 
birth weight infants. Pediatr. Res. 
25:336-38 
55.  Moats-Staats, B. M.,  Brady, J. L.,  Un­
derwood, L. E . ,  D'Ercole, A.  J. 1 984. 
Dietary protein restriction in artificially 
reared neonatal rats causes a reduction in 
insulin-like growth factor I (lGF-I) gene 
expression. Endocrinology 1 25:2368-
74 
56. Nissley, S. P., Rechler, M. M. 1 985. 
Insulin-like growth factors: biosynthe­
sis, receptors and IGF-carrier proteins. 
In Hormonal Proteins and Peptides, ed. 
IGFs AND NUTRITION 41 1 
c. H .  Li, 1 2: 1 27-203 . New York: Aca­
demic 
57 . Ooi, G. T., Orlowski, C. c. , Brown, A. 
L., Becker, R .  E.,  Unterman, T. G . ,  
Rechler, M.  M.  1 990. Different tissue 
distribution and hormonal regulation of 
mRNAs encoding rat insulin-like growth 
factor binding proteins-1 and 2. Mol. 
Endocrinol. 4:32 1-28 
58.  O'Sullivan, U . ,  Gluckman, P. D . ,  
Breier, B .  H . ,  Woodall, S . ,  Siddiqui, R .  
A . ,  McCutcheon, S .  N.  1 989. Insulin­
like growth factor-I (IGF-I) in mice re­
duces weight loss during starvation. 
Endocrinology 125 :2793-94 
59. Pape, G. S.,  Friedman, M . ,  Under­
wood, L. E . ,  Clemmons, D. R. 1 99 1 .  
The effect o f  growth hormone o n  weight 
gain and pulmonary function in patients 
with chronic obstructive lung disease. 
Chest. In press 
60. Phillips, L. S . ,  Young, H .  S .  1976. 
Nutrition and somatomedin. I .  Effects of 
fasting and refeeding on serum somato­
medin activity and cartilage growth 
activity in rats. Endocrinology 99:304-
14 
6\.  Rinderknecht, E . ,  Humbel, R. E. 1978. 
The amino acid sequence of human in­
sulin-like growth factor I and its struc­
tural homology with proinsulin. J. Bioi. 
Chern. 253:2769-76 
62. Rotwein ,  P . ,  Folz, R. H . ,  Gordon, J. I .  
1 987. Biosynthesis of human insulin­
like growth factor I (IGF-I) . J. BioI. 
Chern . 262: 1 1 807-12 
63 . Russell , W .  E . ,  Van Wyk, J .  J., Pled­
ger, W. 1. 1984. Inhibition of the 
mitogenic effects of plasma by a mono­
clonal antibody to somatomedin-C. 
Proc. Natl. Acad. Sci. USA 81 :2389-
92 
64. Salmon, W. D. Jr. ,  Duvall, M. R.  1970. 
In vitro stimulation of leucine incorpora­
tion into muscle and cartilage protein by 
a serum fraction with sulfation factor 
activity: Differentiation of effects from 
those of growth hormone and insulin. 
Endocrinology 87: 1 1 68-80 
65 . Scheiwiller, E . ,  Guier, H .  P . ,  Mer­
ryweather, 1 . ,  Scandella, c . ,  Maerki, 
W . ,  et al 1 986. Growth restoration of 
insulin-deficient diabetic rats by recom­
binant human insulin-like growth factor 
I .  Nature 323 : 1 69-7 1 
66. Smith, A. T., Clemmons, D .  R . ,  Un­
derwood, L. E. , Ben-Ezra, V . ,  McMur­
ray, R. 1987. The effect of exercise on 
somatomedin-C/insulin-like growth fac­
tor I concentrations. Metabolism 36: 
533-37 
67. Snyder, D. K. , Underwood, L. E . ,  
Clemmons, D .  R .  1 990. The anabolic 
A
nn
u.
 R
ev
. N
ut
r. 
19
91
.1
1:
39
3-
41
2.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
412 CLEMMONS & UNDERWOOD 
effects of growth hormone in obese diet­
restricted subjects are dose dependent. 
Am. J. elin. Nutr. 52:431-37 
68. Snyder, D. K. , Clemmons, D. R. 1990. 
Insulin dependent regulation of IGFBP­
I. J. elin. Endocrinol. Metab. 7 1 : 1 632-
36 
69. Snyder, D. K . ,  Clemmons, D. R . ,  Un­
derwood, L. E. 1 988. Treatment of 
obese, diet-restricted subjects with 
growth hormone for 1 1  weeks: Effects 
on anabolism, lipolysis and body com­
position. 1. Clin. Endocrinol. Metab. 
67:54-61 
70. Snyder, D. K . ,  Clemmons, D. R . ,  
Underwood, L. E. 1989. Dietary carbo­
hydrate content determines responsive­
ness to growth hormone in energy­
restricted humans. 1. elin. Endocrinol. 
Metab. 69:745-52 
7 1 .  Stiles, C. D . ,  Capone, G. T . ,  Scher, C . 
D . ,  Antoniades, H. N . ,  Van Wyk, J. J . ,  
Pledger, W. J .  1 979. Dual control of cell 
growth by somatomedin and platelet­
derived growth factor. Proc. Natl. Acad. 
Sci. USA 76: 1279-84 
72. Straus, D. S . ,  Takemoto, C. D. 1990. 
Effect of fasting on insulin-like growth 
factor-I (IGF-I) and growth hormone re­
ceptor mRNA levels and IGF-I gene 
transcription in rat liver. Mol. Endocri­
nolo 4:91-100 
73. Straus, D. S . ,  Takemoto, C. D. 1990. 
Effect of dietary protein deprivation on 
insulin-like growth factor (IGF) I and II, 
IGF binding protein-2 and serum albu­
min gene expression in rat. Endocrinolo­
gy 127:1849-60 
74. Suikkari, A.-M . , Koivisto, V. A . ,  Kois­
tinen, R . ,  Seppala, M . ,  Yki-Jarvinen, 
H. 1 989. Dose-response characteristics 
for suppression of low molecular weight 
plasma insulin-like growth factor­
binding protein by insulin. J. elin. En­
docrinol. Metab. 68: 1 35-40 
75. Suikkari, A.-M.,  Koivisto, V .  A . ,  
Rutanen, E.-M. Yki-Jarvinen, H . ,  
Karonen, S. L., Seppala, M .  1988 . In­
sulin regulates the serum levels of low 
molecular weight insulin-like growth 
factor-binding protein. J. Clin. Endocri­
nol. Metab. 66:266--72 
76. Thissen, J. P . ,  Underwood, L. E. , Mai­
ter, D . ,  Maes, M . ,  Clemmons, D. R . ,  
Ketelslegers, J .  M .  199 1 .  Failure of 
IGF-I infusion to promote growth in pro­
tein-restricted rats despite normalization 
of serum IGF-I concentrations. Endo­
crinology 128:885-90 
77. Thrailkill, K. M . ,  Clemmons, D .  R. , 
Busby, W. H . ,  Handwerger, S. 1 990. 
Differential regulation of insulin-like 
growth factor binding protein secretion 
from human decidual cells by IGF-I, in­
sulin and relaxin. J. elin. Invest. 86: 
878-83 
78. Ullrich, A . ,  Gray, A . ,  Tam, A .  W . ,  
Yang-Feng, T . ,  Tsubokawa, M . ,  et al. 
1 986 . Insulin-like growth factor I recep­
tor primary structure: comparison with 
insulin receptor suggests structural de­
terminants that define functional 
specificity. EMBO J. 5:2503- 1 2  
79. Van Wyk, J .  J .  1984. The somatome­
dins: biological actions and physiologic 
control mechanisms. In Hormonal Pro­
teins and Peptides, ed. C. H. Li, 1 2 : 8 1-
125.  Orlando, Fla.: Academic 
80. Van Wyk, J. J . ,  Underwood, L. E . ,  
Hintz, R. L . ,  Voina, S .  J . ,  Weaver, R .  
P.  1974. The somatomedins: A family of 
insulin-like hormones under growth hor­
mone control. Rec. Prog. Horm. Res. 
30:259-3 1 8  
8 1 .  Ward, H.  C . ,  Halliday, D . ,  Sim, A .  W .  
1987. Protein and energy metabolism 
with biosynthetic human growth hor­
mone after gastrointestinal surgery. Ann. 
Surg. 206:56--61 
82. Zapf, J. , Rinderknecht, E. , Humble, R. 
E.,  Froesch, E. R. 1978. Nonsuppress­
able insulin-like activity (NSILA) from 
human serum: Recent accomplishments 
and their physiologic implications. 
Metabolism 27: 1 803-28 
83. Ziegler, T. R . ,  Young, L. S . ,  Manson, 
J . ,  Wilmore, D. W. 1988. Metabolic 
effects of recombinant human growth 
hormone in patients receiving parenteral 
nutrition. Ann. Surg. 208:6--1 6  
A
nn
u.
 R
ev
. N
ut
r. 
19
91
.1
1:
39
3-
41
2.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 U
ni
ve
rs
ity
 o
f N
or
th
 C
ar
ol
in
a 
- C
ha
pe
l H
ill
 o
n 
04
/0
4/
18
. F
or
 p
er
so
na
l u
se
 o
nl
y.
 
